A Agilent Technologies

Q1 2026 10-Q
Filed: Mar 3, 2026Period ending Jan 31, 2026
Health Care
Laboratory Analytical InstrumentsSEC EDGAR

Agilent Technologies (A) 10-Q quarterly report for Q1 2026, filed with SEC EDGAR on Mar 3, 2026 for the fiscal period ending Jan 31, 2026. This page provides AI-powered analysis including management discussion & analysis (MD&A), risk factor updates, and key quarterly financial data such as revenue and net income extracted from XBRL.

AI Filing Analysis
Q1 2026 10-Q

Management Discussion & Analysis

  • Revenue $1,798M, up 7% YoY; services +9%, products +6%; 3 ppt tailwind from FX
  • Overall operating margin 19.7% vs 22.4% YoY; gross margin 52.6% vs 53.5%; tariffs, restructuring costs, SG&A surge (+16%) key drags
+3 more insights

Risk Factors

  • Tariff/trade risk materially escalated — new explicit language on U.S.-China tariffs, retaliatory measures, and potential trade war with uncertain scope and duration
  • Regulatory risk: GDPR fines up to 4% of total company revenue; also subject to China PIPL, CCPA, and Brazil LGPD across multiple jurisdictions
+3 more insights

Quarterly Financial Summary
XBRL

Revenue

$1.8B

+7.0% YoY

Net Income

$305M

-4.1% YoY

Operating Margin

19.6%

-273bp YoY

Net Margin

17.0%

-195bp YoY

ROE

4.4%

Total Assets

$12.8B

+0.7% QoQ

EPS (Diluted)

$1.07

-3.6% YoY

Operating Cash Flow

$268M

-37.8% YoY

Source: XBRL data from Agilent Technologies Q1 2026 10-Q filing on SEC EDGAR. All figures in USD.

Other Agilent Technologies Quarterly Reports

Get deeper insights on Agilent Technologies

Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.